# Inhibrx Biosciences, Inc. (INBX): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Inhibrx Biosciences, Inc. (INBX) is 5/100, ranked against 24,000+ stocks in 35 markets (Quality 15, Value 25, Momentum 33, each scored against its sector).

- StockRank: 5/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 15, Value 25, Momentum 33: each a 0-100 percentile within Healthcare.
- Position: #25,092 overall, #2,474 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 88.61 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 6.3M; directors sold USD 279K.

Source: https://moatmap.ai/stock/INBX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker